Kybella - Dissolve Facial Fat
Updated: Feb 9, 2019
KYBELLA® is the first FDA approved non-surgical injection for improving the appearance of moderate to severe submental fullness, commonly referred to as double chin. KYBELLA® is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Dr. Michelle Parsons has extensive experience treating patients with Kybella to reduce areas of unwanted facial and submental fullness. Typical facial areas that can be treated with Kybella to improve facial contours, are unwanted extra fat under the chin, fatty jowls and excessive fullness in the nasal labial fold area. Injections with Kybella are performed with very small needles and similar in sensation to injections with Botox. Several seconds after injecting kybella, there is a sensation of heat and ice packs can be applied to improve comfort. The sensation of heat resolves in five to ten minutes. There is typically swelling to the area treated for three to five days, returning to normal after that. Slowly the fat will begin to dissolve in the treated area, and final results can be seen in approximately six weeks. At that time you and Dr. Parsons will re-evaluate the area and determine if further treatment is desired.
KYBELLA® (deoxycholic acid) injection 10 mg/mL is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
KYBELLA is administered by a trained physician who injects the product under a patient’s chin to destroy fat cells, improving the appearance of the patient’s chin area. Up to six treatments may be administered per patient no less than one month apart, and each in-office treatment session lasts approximately twenty minutes.
KYBELLA joins BOTOX® Cosmetic, JUVEDERM® XC, JUVEDERM VOLUMA® XC and LATISSE® as part of the Allergan company.